ERS 2024: Paving the way to true asthma remission

Bosch has conducted FeNO@home, a 12-week multicenter observational study with 85 patients, to assess the additional clinical value of FeNO home monitoring. Initial case reports were presented at ERS 2023. Now, the final results of the study are available. PD Dr. med. Kai-Michael Beeh summarizes the benefits as follows: FeNO home monitoring is an invaluable tool in asthma diagnosis, phenotyping, and treatment optimization. It empowers patients by providing a holistic, objective assessment and enabling trigger identification.

Join the poster session (PS-12, Session 134)!

Contract Research Organizations and study initiators can benefit from FeNO home monitoring in multiple ways. Using the Vivatmo me, they can reduce the expenses for data collection through fewer on-site visits and lower device costs. More FeNO values can be collected during the observation period and the data can be enriched with app-recorded context information such as symptoms, medication, or allergen exposure. The use of more and enriched data can boost clinical insights and enable more flexible study designs.

Let's find out together how we can support your next study!